PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to protect kidneys from devastating autoimmune disease
Disease control Recruiting nowThis study is testing whether a new drug called sefaxersen can slow kidney damage in people with IgA nephropathy who are at high risk of their disease getting worse. Researchers will compare the drug to a placebo in 428 participants over about two years to see if it reduces prote…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Kidney disease patients get extended access to promising drug in safety Follow-Up
Disease control Recruiting nowThis study aims to understand the long-term safety of the drug iptacopan for adults with IgA nephropathy, a kidney disease. It is open to 540 people who have already finished one of two earlier Novartis trials for this drug. The main goal is to monitor side effects for up to 3 ye…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC